Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.

BMC cancer - 10 Jun 2008

Gonçalves Anthony, Esteyries Séverine, Taylor-Smedra Brynn, Lagarde Arnaud, Ayadi Mounay, Monges Geneviève, Bertucci François, Esterni Benjamin, Delpero Jean-Robert, Turrini Olivier, Lelong Bernard, Viens Patrice, Borg Jean-Paul, Birnbaum Daniel, Olschwang Sylviane, Viret Frédéric

Abstract excerpt

BACKGROUND: Cetuximab, a monoclonal antibody targeting Epidermal Growth Factor Receptor (EGFR), is currently used in metastatic colorectal cancer (mCRC), but predictive factors for therapeutic response are lacking. Mutational status of KRAS and EGFR, and EGFR copy number are potential determinant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Disease-Free Survival

Share to Gene Dosage

Share to Genes, ras

Share to Irinotecan

Share to Neoplasm Metastasis

Source

Open in PubMed Open full text

Identifiers

PMID: 18544172
DOI: 10.1186/1471-2407-8-169
PMCID: PMC2432064

Genes

EGFR
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18544172-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.PMID 18544172Read ↗

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.Semantic proximity Read ↗

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.Semantic proximity Read ↗

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.Semantic proximity Read ↗

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.Semantic proximity Read ↗

Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.Semantic proximity Read ↗

The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy.Semantic proximity Read ↗

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patientsSemantic proximity Read ↗

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.Semantic proximity Read ↗

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.Semantic proximity Read ↗

EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer PatientsSemantic proximity Read ↗

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.Semantic proximity Read ↗

Clinical Usefulness of <i>EGFR</i> Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent <i>In situ</i> Hybridization StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.